Page 23 - Nsclc News Today

ROOT, Switzerland, October 15, 2023--Novocure (NASDAQ: NVCR) today announced its participation in the European Society for Medical Oncology (ESMO) Congress 2023 from October 20 – 24 in Madrid. Novocure will present three new posters on Tumor Treating Fields (TTFields) therapy, including an analysis of patient-reported health-related global and functional quality of life scores from the randomized phase 3 LUNAR clinical trial in metastatic non-small cell lung cancer (NSCLC).

Pembrolizumab plus chemotherapy prior to surgery, followed by resection and single-agent pembrolizumab in the adjuvant setting, significantly improved overall survival (OS) vs neoadjuvant placebo plus chemotherapy followed by adjuvant placebo in patients with resectable stage II, IIIA, or IIIB (T3-4N2) non–small cell lung cancer, meeting the dual primary end point of the phase 3 KEYNOTE-671 trial.

Experts discuss the current standard treatment options for patients diagnosed with early-stage NSCLC [non-small cell lung cancer].

Jay Lee, MD, talks about financial toxicity in terms of the individual patient and in terms of the health system itself, especially in terms of non-small cell lung cancer (NSCLC) recurrence.

The FDA has approved encorafenib (Braftovi) plus binimetinib (Mektovi) for adult patients with metastatic non–small cell lung cancer harboring a BRAF V600E mutation, as detected by an FDA-approved test.

Patients with distant recurrent non–small cell lung cancer (NSCLC) had significantly better overall survival (OS) than patients who had de novo disease.

Specialists engage in a conversation regarding the treatment duration and the effectiveness of the current two-year approach.

The single-arm approval study reported an objective response rate of 75% among treatment-naive patients.

The march of immunotherapy into a wider range of malignancies, as well as the smarter use of chemotherapy and novel targeted drugs, will be among the key highlights at the ESMO Congress 2023.

Just as Wall Street had begun mulling the possible fallout of the regulatory vote against full U.S. FDA clearance for Amgen Inc.’s KRAS G12C therapy for non-small-cell lung cancer, a new – albeit not entirely unexpected – development cropped up in the space. Mirati Therapeutics Inc. disclosed Oct. 9 that Bristol Myers Squibb Co. (BMS) is offering to take over the firm in a deal that could be worth as much as $5.8 billion, historically one of the larger takeovers for 2023.